On March 27, 2023 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported a presentation on results of its Phase 1a breast cancer vaccine trial on April 17, 2023, at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Anixa Biosciences, MAR 27, 2023, View Source [SID1234629356]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This 2023 AACR (Free AACR Whitepaper) Annual Meeting will take place April 14-19, 2023 in Orlando, FL, and is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Details of the poster presentation are as follows:
Poster Title: Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer
Poster ID: 3035 / 7
Date/Time: April 17, 2023, 1:30PM-5:00PM ET